N,N-diethyl-2-(4-(2-aminoethyl)phenoxy)ethylamine | 46843-08-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-diethyl-2-(4-(2-aminoethyl)phenoxy)ethylamine
• 英文别名: 2-(4-(2-aminoethyl)phenoxy)-N,N-diethylethanamine；2-[4-[2-(Diethylamino)ethoxy]phenyl]ethanamine
• CAS: 46843-08-7
• 化学式: C₁₄H₂₄N₂O
• mdl: MFCD09705265
• 分子量: 236.357
• InChiKey: ZNLCSYYYVBOUGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2E)-3-(4-氯苯基)丙烯酰氯 、 N,N-diethyl-2-(4-(2-aminoethyl)phenoxy)ethylamine 以 乙腈 为溶剂， 反应 4.0h， 以100%的产率得到N-(2-(4-(2-diethylaminoethoxy)phenyl)ethyl)-4-chlorocinnamide hydrochloride
  参考文献：
  名称：

  Structure−Activity Relationship of N-(Phenylalkyl)cinnamides as Novel NR2B Subtype-Selective NMDA Receptor Antagonists

  摘要：

  A novel series of N-(phenylalkyl)cinnamides related to N-(4-phenylbutyl)-3,4-dihydroxy-beta-cyanocinnamide (6, an EGFR-K inhibitor with high antiproliferative activity) was synthesized and tested for antagonism at N-methyl-D-aspartate (NMDA) receptor subtypes. Potency and subunit selectivity were assayed by electrical recordings in Xenopus oocytes expressing three binary combinations of cloned rat NMDA receptor subunits: NR1A expressed in combination with either NR2A, NR2B, or NR2C. The N-(phenylalkyl)cinnamides are selective antagonists of NR1A/2B receptors. Assayed under steady-state conditions, N-(4-phenylbutyl)-4-hydroxycinnamide (16) has an IC50 value of 77 nM and >1000-fold selectivity with respect to NR1A/2A and NR1A/2C receptors. Potency at alpha(1) adrenergic receptors is low for the four cinnamides tested. Inhibition of NR1A/2B receptors does not correlate with EGFR and ErbB2/neu tyrosine kinase inhibitor activity. The N-(phenylalkyl)cinnamide series we describe provides a novel and structurally diverse framework for designing new NR2B-selective NMDA antagonists as potential CNS therapeutics.

  DOI：

  10.1021/jm990199u
• 作为产物：
  描述：

  N-Boc-酪胺 在 caesium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 4.0h， 生成 N,N-diethyl-2-(4-(2-aminoethyl)phenoxy)ethylamine
  参考文献：
  名称：

  [EN] TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS
  [FR] DÉRIVÉS DE TRIAZOLOTRIAZINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR A2A

  摘要：

  本发明提供了公式（1）的三唑三嗪衍生物作为A2A受体拮抗剂。公式（1）的化合物和包括这些化合物的药物组合物可用于治疗与A2A受体过度功能有关的疾病，如某些类型的癌症。该发明揭示了公式（1）的化合物和制备这些化合物的方法。

  公开号：

  WO2020002969A1

文献信息

• [EN] TROPANE COMPOUNDS<br/>[FR] COMPOSÉS DE TROPANE
  申请人：EXELIXIS INC

  公开号：WO2009055077A1

  公开（公告）日：2009-04-30

  A compound according to Formula I or II: (I) or (II) wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

  根据公式I或II的化合物：（I）或（II），其中R1、R1b、R2、L1和L2以及L2b的定义如规范中所述，以及其药物组合物和使用方法。
• TROPANE COMPOUNDS
  申请人：Exelixis, Inc.

  公开号：EP2074120A1

  公开（公告）日：2009-07-01
• TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS
  申请人：ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD.

  公开号：US20210332055A1

  公开（公告）日：2021-10-28

  The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.